MAX DELBRÜCK CT FÜR MOLEKULARE MEDIZIN has a total of 14 patent applications. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and organic fine chemistry are MAX DELBRUCK CENTRUM FUR MOLEKULARE MEDIZIN IN DER HELMHOLTZ GEMEINSCHAFT, TRIMERIS INC and MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | WIPO (World Intellectual Property Organization) | 7 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Organic fine chemistry | |
#4 | Measurement | |
#5 | Agriculture |
# | Name | Total Patents |
---|---|---|
#1 | Oden Felix | 3 |
#2 | Marino Stephen | 3 |
#3 | Daumke Oliver | 3 |
#4 | Landthaler Markus | 2 |
#5 | Höpken Uta | 2 |
#6 | Müller Gerd | 2 |
#7 | Pezzutto Antonio | 2 |
#8 | Olal Daniel | 2 |
#9 | Lipp Martin | 2 |
#10 | Schmetzer Oliver | 2 |
Publication | Filing date | Title |
---|---|---|
WO2016005589A2 | Novel gene panel for the diagnosis of dilated cardiomyopathy | |
EP3067366A1 | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 | |
EP3061761A1 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | |
EP2914628A1 | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases | |
WO2014044793A2 | Cd22-binding peptides | |
EP2568995A1 | Therapeutic use of agonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth |